rpl44 Antibody

What are the key differences between ERP44 and MRPL44 proteins?

ERP44 (Endoplasmic Reticulum Protein 44, also known as TXNDC4) is a thioredoxin domain-containing protein localized to the endoplasmic reticulum with a molecular weight of approximately 47 kDa (406 amino acids) . It has several synonyms including PDIA10, Thioredoxin Domain-Containing Protein 4, and KIAA0573 . In contrast, MRPL44 (Mitochondrial Ribosomal Protein L44) is a 332 amino acid protein that localizes to the mitochondrion with an observed molecular weight of 38 kDa . MRPL44 is a component of the mitochondrial ribosome's large 39S subunit and plays a role in protein synthesis within the mitochondrion . The fundamental difference is their cellular localization and function: ERP44 in the endoplasmic reticulum and MRPL44 in mitochondria.

What are the common applications for RPL44 antibodies in research?

RPL44 antibodies are utilized in multiple research applications depending on the specific protein target. For ERP44 antibodies, common applications include Western Blotting (WB) with recommended dilutions of 1:1000 . For MRPL44 antibodies, applications are more diverse, including Western Blotting (1:5000-1:50000 dilution), Immunohistochemistry (IHC) at 1:20-1:200 dilution, Immunofluorescence (IF), Immunoprecipitation (IP), and ELISA . These antibodies are essential tools for studying protein expression, localization, and interactions in cellular contexts. They have been used in published research for detecting these proteins in various cell lines including A549, HeLa, Jurkat, and K-562 cells, as well as in tissue samples such as rat brain and human ovary tumor tissue .

What species reactivity should I consider when selecting an RPL44 antibody?

When selecting an antibody, species reactivity is a critical consideration to ensure experimental success. For ERP44 antibodies, product #2886 from Cell Signaling Technology demonstrates reactivity with Human, Mouse, Rat, and Monkey samples . Other ERP44 antibodies may have more limited reactivity, such as the Proteintech product 67426-2-PBS which is reported to have human reactivity only . For MRPL44 antibodies, the Proteintech product 16394-1-AP has been tested and confirmed to react with human, mouse, and rat samples, with cited reactivity also including monkey, zebrafish, and yeast models . Always verify the specific reactivity of your selected antibody against your experimental model organism to ensure proper antigen recognition.

How should I design Western blot experiments using RPL44 antibodies?

For optimal Western blot results with RPL44 antibodies, several methodological considerations are essential. When using ERP44 antibodies, a dilution of 1:1000 is typically recommended , while MRPL44 antibodies may require higher dilutions (1:5000-1:50000) . For sample preparation, validated positive controls include A549 cells, HeLa cells, Jurkat cells, and K-562 cells for MRPL44 . Expected molecular weights are 44 kDa for ERP44 and 38 kDa for MRPL44 , which should be used as reference points when interpreting bands. For improved sensitivity and specificity, consider using antibody pairs specifically designed for immunoprecipitation followed by Western blot detection, such as the Mouse Monoclonal Anti-TXNDC4 for immunoprecipitation followed by Rabbit Polyclonal Anti-TXNDC4 for detection in Western blots . This approach can help reduce background and increase signal specificity, particularly in complex samples or when studying low-abundance proteins.

What are the optimal conditions for immunohistochemistry with MRPL44 antibodies?

For successful immunohistochemistry (IHC) using MRPL44 antibodies, tissue preparation and antigen retrieval are critical steps. MRPL44 antibody 16394-1-AP has been validated for IHC at dilutions of 1:20-1:200 . The suggested antigen retrieval method is with TE buffer pH 9.0, although citrate buffer pH 6.0 may be used as an alternative . Positive IHC detection has been confirmed in human ovary tumor tissue . For optimal results, researchers should perform a titration of the antibody concentration to determine the ideal dilution for their specific tissue samples. The fixation method should be compatible with the antibody; typically, formalin-fixed paraffin-embedded (FFPE) tissues work well, but this should be verified for each experimental setup. Additionally, appropriate negative controls (omitting primary antibody) and positive controls (tissues known to express the target protein) should be included to validate staining specificity.

How can I optimize immunofluorescence experiments for studying MRPL44 localization?

For immunofluorescence studies of MRPL44 localization, a methodological approach similar to that described in search result can be effective. When studying mitochondrial proteins like MRPL44, co-localization with mitochondrial markers is essential to confirm proper localization. Cells expressing GFP-tagged MRPL44 can be grown on gelatin-coated coverslips, and MitoTrackerRed can be added to cultures 30 minutes prior to harvesting to stain the mitochondria . After PBS washing and paraformaldehyde fixation, cells can be immunostained with an anti-GFP antibody if using GFP-tagged constructs . DAPI staining should be used to visualize the nucleus. Images can be captured on a widefield fluorescence microscope or, preferably, a confocal microscope for higher resolution of subcellular structures. For non-GFP tagged versions, direct immunostaining with MRPL44 antibodies can be performed, followed by appropriate fluorophore-conjugated secondary antibodies. The optimal dilution for immunofluorescence with MRPL44 antibody should be determined experimentally, but published studies have successfully used this approach .

How can I use RPL44 antibodies in multiplex assays for comprehensive protein analysis?

For advanced multiplex protein analysis, ERP44 antibodies in the format 67426-2-PBS are particularly well-suited as they are designed as part of matched antibody pairs (MP50988-1 and MP50988-2) . These unconjugated mouse monoclonal antibodies at a concentration of 1 mg/mL are ready for conjugation to various reporter molecules . To implement multiplex assays, researchers can conjugate different antibodies to distinct fluorophores or other detectable tags for simultaneous detection of multiple proteins. The conjugation-ready format makes these antibodies ideal for cytometric bead arrays, where 67426-2-PBS can be used as capture antibody with either 67426-3-PBS or 67426-4-PBS as detection antibodies . For mass cytometry applications, antibodies can be labeled with different metal isotopes. When designing multiplex imaging experiments, careful consideration must be given to antibody cross-reactivity and spectral overlap of detection systems. Optimization should include titration of each antibody and validation of specificity in the multiplex format to ensure accurate results.

What strategies can I use to study protein-protein interactions involving MRPL44?

To investigate protein-protein interactions involving MRPL44, immunoprecipitation (IP) followed by mass spectrometry or Western blot analysis is a powerful approach. The MRPL44 antibody 16394-1-AP has been validated for IP applications in published research . For co-immunoprecipitation experiments, a protocol similar to that used in search result can be adapted. HEK293T cells can be transfected using calcium phosphate method for co-IP experiments . FLAG or GFP-tagged MRPL44 constructs can be expressed in cells, followed by immunoprecipitation using anti-FLAG or anti-GFP antibodies. Alternatively, endogenous MRPL44 can be immunoprecipitated using specific antibodies. The precipitated complexes can then be analyzed by Western blotting to detect potential interaction partners. For more comprehensive analysis, immunoprecipitated complexes can be subjected to mass spectrometry. Cross-linking approaches prior to immunoprecipitation can help capture transient interactions. Proximity-based labeling methods such as BioID or APEX2 fused to MRPL44 can also be employed to identify proteins in close proximity to MRPL44 in living cells.

How can I investigate the role of MRPL44 in mitochondrial ribosome assembly and function?

Investigating MRPL44's role in mitochondrial ribosome assembly requires a multi-faceted approach combining genetic manipulation and biochemical analysis. Given that MRPL44 contains RNase III domains and is associated with mitochondrial ribosomes , researchers can employ RNA immunoprecipitation (RIP) to identify RNA interactions. Knockdown experiments using shRNAs targeting sequences at the 3' UTR (5'-TCTCTTACACACTGGTTTATTACT-3') or the open reading frame (5'-GGAAAGAGCTCTTTGAGATGT-3') can reveal the functional consequences of MRPL44 depletion . After knockdown, mitochondrial translation can be assessed by metabolic labeling with 35S-methionine in the presence of cycloheximide to inhibit cytosolic translation. Sucrose gradient centrifugation can be used to analyze ribosome profiles and assess the impact of MRPL44 depletion on mitochondrial ribosome assembly. For localization studies, immunofluorescence microscopy with MRPL44-GFP fusion proteins and MitoTrackerRed can confirm mitochondrial localization . Complementation experiments with wild-type versus mutant MRPL44 can provide insights into structure-function relationships. Mass spectrometry analysis of mitochondrial ribosomes isolated from control versus MRPL44-depleted cells can identify changes in ribosome composition.

How can I address non-specific binding issues with RPL44 antibodies?

Non-specific binding is a common challenge when working with antibodies. For RPL44 antibodies, several methodological approaches can minimize this issue. First, optimize blocking conditions by testing different blocking agents (BSA, non-fat milk, commercial blocking buffers) and concentrations (3-5%). For Western blotting with ERP44 antibodies, the recommended 1:1000 dilution should be carefully titrated , while MRPL44 antibodies may require higher dilutions (1:5000-1:50000) to reduce background. Including additional washing steps with increased detergent concentration (0.1-0.3% Tween-20) can help remove non-specifically bound antibodies. For immunoprecipitation experiments, pre-clearing lysates with protein A/G beads before adding specific antibodies can reduce non-specific binding. When conducting immunohistochemistry, antigen retrieval methods significantly impact specificity; for MRPL44 antibodies, TE buffer pH 9.0 is recommended, with citrate buffer pH 6.0 as an alternative . Always include appropriate negative controls (isotype controls or tissues/cells not expressing the target) to distinguish between specific and non-specific signals. For particularly challenging samples, consider using highly purified antibodies or antibody fragments (Fab) to minimize non-specific interactions.

What are the best practices for storage and handling of RPL44 antibodies to maintain activity?

Proper storage and handling of antibodies are critical for maintaining their activity and ensuring reproducible results. ERP44 antibody 67426-2-PBS should be stored at -80°C , while MRPL44 antibody 16394-1-AP should be stored at -20°C and remains stable for one year after shipment . For the latter, aliquoting is unnecessary for -20°C storage . When working with antibodies, avoid repeated freeze-thaw cycles by preparing small working aliquots. MRPL44 antibody is supplied in PBS with 0.02% sodium azide and 50% glycerol pH 7.3 , which helps maintain stability. When diluting antibodies for use, prepare fresh working solutions in appropriate buffers containing stabilizers (such as BSA) and keep them cold during experiments. For long-term storage, ensure that freezers maintain consistent temperatures without defrost cycles. Always centrifuge antibody vials briefly before opening to collect the liquid at the bottom of the vial. Monitor the performance of antibodies over time by including positive controls in each experiment to detect any loss of activity. If decreased activity is observed, consider purchasing a new lot of antibody rather than increasing the concentration, as this might lead to increased background.

How can I validate the specificity of my RPL44 antibody results?

Validating antibody specificity is essential for ensuring the reliability of experimental results. For RPL44 antibodies, multiple validation approaches should be employed. First, genetic validation through knockdown or knockout of the target protein using shRNAs or CRISPR-Cas9 should eliminate or significantly reduce the signal in Western blot, immunohistochemistry, or immunofluorescence experiments . Second, use multiple antibodies targeting different epitopes of the same protein; concordant results strengthen confidence in specificity. Third, include positive controls (cell lines or tissues known to express the target) and negative controls (tissues or cells not expressing the target) in each experiment. Fourth, for immunofluorescence or immunohistochemistry studies of MRPL44, co-localization with established mitochondrial markers should be demonstrated . For ERP44, co-localization with ER markers would be expected. Fifth, recombinant protein expression can be used as a positive control, comparing the molecular weight with endogenous protein. Finally, mass spectrometry analysis of immunoprecipitated proteins can confirm the identity of the target protein. When publishing results, it is increasingly important to report detailed validation methods to address the growing concern about antibody specificity in the scientific community.

How do monoclonal and polyclonal RPL44 antibodies compare in different applications?

The choice between monoclonal and polyclonal antibodies significantly impacts experimental outcomes and should be based on the specific research application. For ERP44, both monoclonal and polyclonal antibodies are available; for example, Mouse Monoclonal Anti-TXNDC4 for immunoprecipitation and Rabbit Polyclonal Anti-TXNDC4 for Western blot detection . For MRPL44, polyclonal antibodies like 16394-1-AP (Rabbit/IgG) are available . Monoclonal antibodies offer high specificity for a single epitope, resulting in less background and batch-to-batch consistency, making them ideal for quantitative applications and detecting specific protein forms. This is illustrated by the monoclonal ERP44 antibody (67426-2-PBS) designed for precise applications like cytometric bead arrays . Polyclonal antibodies recognize multiple epitopes, potentially providing stronger signals through cumulative binding and greater tolerance to protein denaturation or modifications. The polyclonal MRPL44 antibody demonstrates this versatility with successful application across WB, IHC, IF, IP, and ELISA . For Western blotting, polyclonal antibodies often provide stronger signals but may show more background, while monoclonals offer cleaner results but potentially weaker signals. For immunoprecipitation, the ideal approach may be using monoclonal antibodies for the pull-down (high specificity) and polyclonal antibodies for detection (stronger signal), as demonstrated in the ERP44 antibody pair system .

What considerations are important when selecting between different RPL44 antibody formats for imaging applications?

For imaging applications studying RPL44 proteins, several antibody format considerations significantly impact experimental success. When selecting antibodies for immunofluorescence of ERP44 (endoplasmic reticulum) or MRPL44 (mitochondria), primary consideration should be given to antibody species compatibility with secondary detection systems. For instance, the rabbit-derived MRPL44 antibody requires anti-rabbit secondary antibodies, while mouse-derived ERP44 antibodies need anti-mouse secondaries. For multi-color imaging, antibodies derived from different host species enable simultaneous detection of multiple targets without cross-reactivity. Alternative approaches include using directly conjugated primary antibodies, though these may provide lower sensitivity than the primary-secondary approach. For super-resolution microscopy, antibody fragment formats (Fab, scFv) may be preferable due to their smaller size, reducing the distance between fluorophore and target and improving spatial resolution. For live-cell imaging of RPL44 proteins, genetically encoded tags like GFP-tagged MRPL44 offer advantages over antibodies, as they allow visualization in living cells without fixation and permeabilization. When studying protein dynamics, photoactivatable or photoswitchable fluorescent proteins fused to the target offer superior capabilities for tracking movement and turnover. Finally, proximity-based techniques like Proximity Ligation Assay (PLA) using oligonucleotide-conjugated secondary antibodies can detect protein-protein interactions with high sensitivity and spatial resolution, providing functional insights beyond simple localization.

How should I interpret discrepancies in RPL44 antibody results between different experimental techniques?

When faced with discrepancies in RPL44 antibody results across different techniques, a systematic analytical approach is essential. First, consider technique-specific factors: Western blotting detects denatured proteins, potentially exposing epitopes hidden in native conformations, while immunofluorescence and immunohistochemistry typically detect native or partially denatured proteins. For example, an MRPL44 antibody might detect the protein in Western blot at 38 kDa but show different staining patterns in IHC due to fixation-induced conformational changes. Second, evaluate antibody-specific properties: different antibodies target different epitopes, which may be differentially accessible depending on protein conformation, fixation method, or protein-protein interactions. The polyclonal MRPL44 antibody 16394-1-AP recognizes multiple epitopes , potentially yielding different results than a monoclonal antibody targeting a single epitope. Third, consider experimental conditions: buffer composition, detergents, fixation methods, and antigen retrieval techniques (like the recommended TE buffer pH 9.0 for MRPL44 IHC ) significantly impact epitope accessibility. Fourth, assess post-translational modifications: phosphorylation, glycosylation, or proteolytic processing may alter antibody recognition in tissue-specific or condition-specific manners. Finally, explore biological explanations: apparent discrepancies might reflect genuine biological differences in protein localization, expression, or interaction states across different conditions. To resolve discrepancies, employ multiple antibodies targeting different epitopes, validate with genetic approaches (knockdown/knockout), and use complementary techniques like mass spectrometry for unbiased protein identification.

How can I incorporate RPL44 antibody data into broader studies of mitochondrial or ER function?

Integrating RPL44 antibody data into comprehensive studies of organelle function requires thoughtful experimental design and contextual interpretation. For MRPL44, which functions in mitochondrial ribosomes , antibody data should be correlated with mitochondrial translation efficiency measurements using metabolic labeling with 35S-methionine in the presence of cycloheximide. Changes in MRPL44 levels detected by Western blotting can be analyzed alongside mitochondrial respiratory complex activities measured by enzymatic assays or respirometry to establish functional relationships. Immunofluorescence co-localization studies with MitoTrackerRed can be extended to include markers of mitochondrial dynamics (fusion/fission) or stress responses. For ERP44, which functions in the endoplasmic reticulum , antibody-detected expression or localization changes should be correlated with ER stress markers (BiP/GRP78, CHOP, XBP1 splicing) and protein secretion efficiency. Multi-omics approaches are particularly powerful; antibody-based proteomics data can be integrated with transcriptomics to identify discordances between mRNA and protein levels, suggesting post-transcriptional regulation. Phospho-specific antibodies, if available, can reveal activation states correlated with functional readouts. Time-course experiments are valuable for distinguishing cause-effect relationships; for example, determining whether MRPL44 level changes precede or follow mitochondrial dysfunction. Finally, perturbation experiments using the validated shRNA sequences targeting MRPL44 combined with phenotypic assays provide causal insights that strengthen correlative antibody data.

What recent scientific advances have been made using RPL44 antibodies in research?

Recent research utilizing RPL44 antibodies has yielded significant advances in understanding both ERP44 and MRPL44 biology. For MRPL44, published work cited in search result has established its crucial role in mitochondrial ribosome assembly and function. The antibody 16394-1-AP has been used in 36 Western blot applications, 1 immunofluorescence study, and 2 immunoprecipitation experiments documented in recent publications . These studies have revealed that MRPL44, containing RNase III domains , plays a role beyond structural components of mitochondrial ribosomes, potentially involving RNA processing activities. This dual structural-enzymatic function places MRPL44 at a critical junction of mitochondrial gene expression regulation. Furthermore, research has expanded beyond human models to include mouse, rat, monkey, zebrafish, and even yeast systems , highlighting evolutionary conservation of MRPL44 functions. For ERP44, recent studies have utilized antibodies to elucidate its role in protein quality control within the secretory pathway. As a thioredoxin domain-containing protein , ERP44 participates in redox regulation and proper folding of disulfide-containing proteins. The species cross-reactivity of ERP44 antibodies with human, mouse, rat, and monkey samples has facilitated comparative studies across model organisms. The availability of matched antibody pairs for ERP44 has enabled quantitative assessments in multiplex assays and cytometric bead arrays, advancing our understanding of ERP44 dynamics in different physiological and pathological contexts.

How might new antibody technologies enhance RPL44 protein research in the near future?

Emerging antibody technologies promise to revolutionize RPL44 protein research through several innovative approaches. Single-domain antibodies (nanobodies) derived from camelid species offer significantly smaller size (~15 kDa versus ~150 kDa for conventional antibodies), enabling access to sterically hindered epitopes in crowded cellular environments like mitochondria (for MRPL44) or the endoplasmic reticulum (for ERP44). These nanobodies could be engineered with site-specific conjugation chemistry for precise attachment of fluorophores, enzymes, or other detection moieties. Synthetic antibody mimetics, including designed ankyrin repeat proteins (DARPins) and affibodies, provide alternatives with potentially higher stability and expression yields in recombinant systems, addressing some limitations of current MRPL44 and ERP44 antibodies. DNA-barcoded antibodies would enable highly multiplexed protein detection far beyond current capabilities, allowing simultaneous profiling of RPL44 proteins alongside hundreds of other targets in single samples. For functional studies, "pro-body" technologies featuring protease-activatable antibodies could allow conditional recognition of RPL44 proteins only in specific cellular compartments where relevant proteases are active. Split-antibody complementation systems could enable detection of protein-protein interactions involving MRPL44 or ERP44 with spatial resolution in living cells. Finally, antibody-enzyme fusions that catalyze proximity-dependent labeling (similar to APEX or BioID approaches) would allow mapping of the dynamic interactome of these proteins in living cells under various physiological and pathological conditions.

What are promising directions for studying post-translational modifications of RPL44 proteins?

Post-translational modifications (PTMs) of RPL44 proteins represent an underexplored area with significant potential for understanding regulatory mechanisms. A comprehensive strategy would begin with mass spectrometry-based proteomics to map the PTM landscape of MRPL44 and ERP44, identifying sites of phosphorylation, acetylation, ubiquitination, SUMOylation, and other modifications. Once specific modification sites are identified, modification-specific antibodies could be developed - particularly for recurring, regulatory modifications. For example, phospho-specific antibodies against potential regulatory phosphorylation sites in MRPL44 could reveal condition-dependent activation states. Site-directed mutagenesis of identified PTM sites (converting modifiable residues to non-modifiable ones or to phosphomimetic residues) coupled with functional assays would establish causative relationships between modifications and protein function. For studying dynamic changes, techniques like SILAC (Stable Isotope Labeling with Amino acids in Cell culture) or TMT (Tandem Mass Tag) labeling coupled with immunoprecipitation using existing RPL44 antibodies would enable quantitative tracking of modification changes under different conditions or treatments. Proximity-dependent labeling methods like BioID fused to writers or erasers of specific modifications could identify enzymes responsible for regulating RPL44 protein modifications. Finally, reconstitution systems using purified components would allow mechanistic studies of how specific modifications affect protein-protein interactions, enzymatic activities (particularly relevant for MRPL44's potential RNase activity ), or subcellular localization.

How can integrative multi-omics approaches incorporate RPL44 antibody data for systems-level insights?

Integrative multi-omics approaches incorporating RPL44 antibody data can provide unprecedented systems-level insights into cellular function. A comprehensive strategy would combine antibody-based proteomics with transcriptomics, metabolomics, and functional genomics. First, quantitative proteomics using RPL44 antibodies for immunoprecipitation followed by mass spectrometry can identify condition-specific protein interaction networks. For MRPL44, this approach would reveal connections within the mitochondrial translation machinery and potentially unexpected interactions with other cellular pathways. For ERP44, it would illuminate the protein quality control network within the secretory pathway. Second, integrating this interactome data with transcriptomics (RNA-seq) can identify concordant or discordant changes at protein versus mRNA levels, revealing post-transcriptional regulatory mechanisms. Third, spatial transcriptomics and proteomics can map the tissue-specific expression patterns of RPL44 proteins and their partners. Fourth, metabolomics data can be correlated with MRPL44 levels to understand how mitochondrial translation impacts cellular metabolism. Fifth, CRISPR screens can identify genetic interactions with RPL44 genes, revealing functional relationships and pathway dependencies. The technical implementation would involve computational integration of these diverse data types using network analysis, machine learning approaches for pattern recognition, and causal inference methods to establish directional relationships between molecular events. This integrated approach would position RPL44 proteins within the broader cellular system, revealing emergent properties and unexpected connections that cannot be discerned from single-omics approaches.